Rosen Law Firm Announces Class Action Lawsuit for Capricor Therapeutics Investors

Capricor Investors Have Opportunity to Lead Class Action

In a significant development for investors, Rosen Law Firm has announced a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR), which may provide an opportunity for affected shareholders to seek justice and compensation. The lawsuit is on behalf of those who purchased Capricor securities between December 17, 2025, and July 26, 2026, as part of an ongoing effort to address potential securities fraud within the company.

Why This Lawsuit Matters

The class action lawsuit has been filed after serious allegations came to light regarding Capricor's communications and business practices. Investors purchasing shares during the specified time frame are encouraged to consider their rights and the implications of this legal action. The deadline to move the court for lead plaintiff status is September 28, 2026, marking a critical date for active participants.

What’s at Stake

If you bought Capricor securities during the class period, you might be entitled to compensation without having to pay upfront legal fees. The Rosen Law Firm operates on a contingency fee basis, which means that fees are paid only if there is a successful recovery. This structure allows investors to pursue claims without financial risk.

Leading the Charge

Rosen Law Firm emphasizes its extensive experience in representing investors worldwide, particularly in securities class actions and shareholder derivative suits. Their track record speaks for itself, having secured large settlements for investors in the past, including a record settlement against a Chinese company. The firm has been consistently acknowledged as a leader in this space, achieving a top ranking for securities class action settlements each year since 2013.

Allegations Against Capricor

Central to the allegations is the assertion that Capricor made materially false and misleading statements about its business operations. Specific claims include:
1. Changes to a statistical analysis plan for studying clinical data linked to their cell therapy, Deramiocel, were not pre-approved by the FDA.
2. This lack of prior agreement posed a risk that the FDA might find the clinical results insufficient to support the therapy's efficacy.
3. Consequently, there is significant uncertainty regarding Deramiocel's regulatory approval for treating Duchenne muscular dystrophy, which impacts both investors' confidence and Capricor’s market performance.

These allegations paint a concerning picture of Capricor's operational integrity, leading to serious implications for investors who thought they were engaging with a reputable company.

What You Can Do

Investors wishing to join the Capricor class action suit should act swiftly. They can visit Rosen Law Firm's official website to learn more about the process or contact Phillip Kim, Esq. toll-free at 866-767-3653 for personalized support. It's important to note that no class has yet been certified, and potential class members are encouraged to seek appropriate counsel.

Stay Updated

For real-time updates on this case and other actions undertaken by the Rosen Law Firm, interested parties should follow their social media pages on LinkedIn, Twitter, and Facebook. It’s crucial for investors to stay informed as developments unfold in this significant legal matter.

In conclusion, the class action lawsuit regarding Capricor Therapeutics, Inc., provides a crucial channel for investors who feel aggrieved by potential securities fraud. As details continue to emerge, the actions taken by investors could influence the outcome of this lawsuit, making participation an essential consideration for those affected.